U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H16NO3.Cl
Molecular Weight 197.66
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOCARNITINE HYDROCHLORIDE

SMILES

[Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O

InChI

InChIKey=JXXCENBLGFBQJM-FYZOBXCZSA-N
InChI=1S/C7H15NO3.ClH/c1-8(2,3)5-6(9)4-7(10)11;/h6,9H,4-5H2,1-3H3;1H/t6-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H15NO3
Molecular Weight 161.1989
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

CNS Activity

Curator's Comment: Known to be CNS penetrant in model animals. Human data not available.

Originator

Sources: www.ncbi.nlm.nih.gov/pubmed/16857830http://adisinsight.springer.com/drugs/800003253

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P50416
Gene ID: 1374.0
Gene Symbol: CPT1A
Target Organism: Homo sapiens (Human)
Target ID: P23786
Gene ID: 1376.0
Gene Symbol: CPT2
Target Organism: Homo sapiens (Human)
Target ID: P43155
Gene ID: 1384.0
Gene Symbol: CRAT
Target Organism: Homo sapiens (Human)
Target ID: O43772
Gene ID: 788.0
Gene Symbol: SLC25A20
Target Organism: Homo sapiens (Human)
Target ID: WP408
Sources: DOI: 10.1201/b17092-12
Target ID: WP623
Sources: DOI: 10.1201/b17092-12
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARNITOR

Approved Use

CARNITOR (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency.

Launch Date

1985
Primary
Dromos

Approved Use

It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enchancement in patients with chronic congestive heart failure.
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
79.2 nmol/mL
330 mg 2 times / day multiple, oral
dose: 330 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOCARNITINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
80.3 nmol/mL
2 g 2 times / day multiple, oral
dose: 2 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOCARNITINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
771.4 nmol × h/mL
330 mg 2 times / day multiple, oral
dose: 330 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOCARNITINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
779.9 nmol × h/mL
2 g 2 times / day multiple, oral
dose: 2 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOCARNITINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
1987
Carnitine deficiency associated with long-term pivampicillin treatment: the effect of a replacement therapy regime.
1992 Nov
Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage.
1994 Apr
Effect of L-carnitine supplementation on acute valproate intoxication.
1996 Jul
L-carnitine supplementation in patients with cystic acne on isotretinoin therapy.
1999 Nov
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
2003 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats.
2006 Aug
Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.
2006 Feb
Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine.
2006 Mar
High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.
2008 Jun
Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats.
2010 Jan
The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells.
2011 Jun 24
L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells.
2011 May 15
Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.
2012
The protection role of heat shock protein 70 (HSP-70) in the testes of cadmium-exposed rats.
2012
L-Carnitine rescues ketamine-induced attenuated heart rate and MAPK (ERK) activity in zebrafish embryos.
2012 Apr
Patents

Sample Use Guides

Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response. Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Route of Administration: Oral
Human neuroblastoma or human astrocytoma cells were exposed to 100 nM (20 ug levocarnetine hydrochloride/L) to 100 uM (20 mg levocarnetine hydrochloride/L). At these concentrations levocarnetine produced significant increases in mitochondrial function.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:20:30 GMT 2023
Edited
by admin
on Fri Dec 15 17:20:30 GMT 2023
Record UNII
J3Y5E6IKS3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOCARNITINE HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
SELTZER CHEMICALS L-CARNITINE HCL
Brand Name English
CARNITINE HCL [INCI]
Common Name English
L-CARNITINE HYDROCHLORIDE
Systematic Name English
LEVOCARNITINE HYDROCHLORIDE [MART.]
Common Name English
LEVOCARNITINE CHLORIDE [JAN]
Common Name English
LEVOCARNITINE HCL
Common Name English
CARNITINE HYDROCHLORIDE [MI]
Common Name English
LEVOCARNITINE CHLORIDE
JAN  
Common Name English
CARNITINE HCL
INCI  
INCI  
Official Name English
(2R)-3-CARBOXY-2-HYDROXY-N,N,N-TRIMETHYL-1-PROPANAMINIUM INNER SALT HYDROCHLORIDE
Common Name English
CARNITINE HYDROCHLORIDE, L-
Systematic Name English
Levocarnitine hydrochloride [WHO-DD]
Common Name English
ORISTAR LCH
Brand Name English
Code System Code Type Description
SMS_ID
100000086667
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
PUBCHEM
656657
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
RXCUI
1426681
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
229-663-6
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
EVMPD
SUB01064MIG
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
DRUG BANK
DBSALT001037
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
MERCK INDEX
m3119
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY Merck Index
DAILYMED
J3Y5E6IKS3
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL1149
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
FDA UNII
J3Y5E6IKS3
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
CAS
6645-46-1
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID701014449
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
EVMPD
SUB02906MIG
Created by admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY